HQY-2014-10-31 10Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
| |
ý | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended October 31, 2014
OR
|
| |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission File Number: 001-36568
|
| | | | |
Delaware | | 7389 | | 52-2383166 |
(State or other jurisdiction of incorporation or organization) | | (Primary Standard Industrial Classification Code Number) | | (I.R.S. Employer Identification Number) |
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(877) 694-3942
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (“Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨
Indicate by check mark whether the registrant has submitted electronically and posted to its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|
| | | |
Large accelerated filer | ¨ | Accelerated filer | ¨ |
Non-accelerated filer | þ (Do not check if a smaller reporting company) | Smaller reporting company | ¨ |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ
As of November 30, 2014, there were 54,753,740 shares of the registrant's common stock outstanding.
HealthEquity, Inc. and subsidiaries
Form 10-Q quarterly report
Table of contents
|
| | |
| | Page |
Part I. FINANCIAL INFORMATION | |
Item 1. | | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
Item 3. | | |
Item 4. | | |
Part II. OTHER INFORMATION | |
Item 1. | | |
Item 1A. | | |
Item 2. | | |
Item 6. | | |
| | |
| | |
Part I. Financial information
Item 1. Financial statements
HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets (unaudited)
|
| | | | | | | |
(in thousands, except par value) | October 31, 2014 |
|
| January 31, 2014 |
|
Assets |
|
|
|
Current assets |
|
|
|
Cash and cash equivalents | $ | 107,854 |
|
| $ | 13,917 |
|
Accounts receivable, net of allowance for doubtful accounts of $40 as of October 31, 2014 and January 31, 2014 | 6,054 |
|
| 5,705 |
|
Inventories | 756 |
|
| 391 |
|
Deferred tax asset | 1,392 |
|
| 3,080 |
|
Prepaid expenses | 2,787 |
|
| 663 |
|
Total current assets | 118,843 |
|
| 23,756 |
|
Property and equipment, net | 2,688 |
|
| 1,992 |
|
Intangible assets, net | 26,250 |
|
| 24,691 |
|
Goodwill | 4,651 |
|
| 4,651 |
|
Other investments | 305 |
|
| — |
|
Total assets | $ | 152,737 |
|
| $ | 55,090 |
|
Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) |
|
|
|
Current liabilities |
|
|
|
Accounts payable | $ | 908 |
|
| $ | 2,368 |
|
Accrued compensation | 3,009 |
|
| 4,134 |
|
Accrued liabilities | 2,419 |
|
| 2,927 |
|
Total current liabilities | 6,336 |
|
| 9,429 |
|
Long-term liabilities |
|
|
|
Deferred rent | 481 |
|
| 393 |
|
Series D-3 redeemable convertible preferred stock derivative liability | — |
|
| 6,182 |
|
Deferred tax liability | 5,416 |
|
| 5,078 |
|
Total long-term liabilities | 5,897 |
|
| 11,653 |
|
Total liabilities | 12,233 |
|
| 21,082 |
|
Commitments and contingencies (see note 5) |
|
|
|
Redeemable convertible preferred stock |
|
|
|
Redeemable convertible preferred stock, $0.0001 par value, 26,473 shares authorized; no shares issued and outstanding as of October 31, 2014 and 17,349 shares issued and outstanding as of January 31, 2014; liquidation preference of $0 and $43,128 as of October 31, 2014 and January 31, 2014, respectively | — |
|
| 46,714 |
|
Stockholders’ equity (deficit) |
|
|
|
Convertible preferred stock, $0.0001 par value, 6,738 shares authorized, no shares issued and outstanding as of October 31, 2014 and 6,156 shares issued and outstanding as of January 31, 2014; liquidation preference of $0 and $12,764 as of October 31, 2014 and January 31, 2014, respectively | — |
|
| 8,129 |
|
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of October 31, 2014 and January 31, 2014, respectively | — |
|
| — |
|
Common stock, $0.0001 par value, 900,000 shares authorized, 54,754 and 7,038 shares issued and outstanding as of October 31, 2014 and January 31, 2014, respectively | 5 |
|
| 1 |
|
Common stock warrants | — |
|
| 2,334 |
|
Additional paid-in capital | 154,874 |
|
| — |
|
Accumulated deficit | (14,375 | ) |
| (23,170 | ) |
Total stockholders’ equity (deficit) | 140,504 |
|
| (12,706 | ) |
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $ | 152,737 |
|
| $ | 55,090 |
|
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and
comprehensive income (unaudited)
|
| | | | | | | | | | | | | | | |
(in thousands, except per share data) | Three months ended October 31, | |
| Nine months ended October 31, | |
2014 |
|
| 2013 |
|
| 2014 |
|
| 2013 |
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
|
|
|
Account fee revenue | $ | 11,086 |
|
| $ | 7,496 |
|
| $ | 32,022 |
|
| $ | 21,721 |
|
Custodial fee revenue | 6,196 |
|
| 4,816 |
|
| 17,557 |
|
| 13,913 |
|
Card fee revenue | 4,317 |
|
| 2,853 |
|
| 12,848 |
|
| 8,929 |
|
Other revenue | 263 |
|
| 83 |
|
| 557 |
|
| 291 |
|
Total revenue | 21,862 |
|
| 15,248 |
|
| 62,984 |
|
| 44,854 |
|
|
|
|
|
|
|
|
|
Cost of services |
|
|
|
|
|
|
|
Account costs | 7,057 |
|
| 4,977 |
|
| 20,188 |
|
| 14,677 |
|
Custodial costs | 1,050 |
|
| 858 |
|
| 2,994 |
|
| 2,737 |
|
Card costs | 1,467 |
|
| 1,006 |
|
| 4,284 |
|
| 2,989 |
|
Other costs | 56 |
|
| 29 |
|
| 58 |
|
| 71 |
|
Total cost of services | 9,630 |
|
| 6,870 |
|
| 27,524 |
|
| 20,474 |
|
|
|
|
|
|
|
|
|
Gross profit | 12,232 |
|
| 8,378 |
|
| 35,460 |
|
| 24,380 |
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
Sales and marketing | 2,275 |
|
| 1,876 |
|
| 6,829 |
|
| 5,458 |
|
Technology and development | 2,811 |
|
| 1,803 |
|
| 7,299 |
|
| 5,131 |
|
General and administrative | 2,443 |
|
| 894 |
|
| 5,252 |
|
| 2,629 |
|
Amortization of acquired intangible assets | 409 |
|
| 409 |
|
| 1,227 |
|
| 1,227 |
|
Total operating expenses | 7,938 |
|
| 4,982 |
|
| 20,607 |
|
| 14,445 |
|
|
|
|
|
|
|
|
|
Income from operations | 4,294 |
|
| 3,396 |
|
| 14,853 |
|
| 9,935 |
|
|
|
|
|
|
|
|
|
Other expense |
|
|
|
|
|
|
|
Loss on revaluation of redeemable convertible preferred stock derivative | — |
|
| (109 | ) |
| (735 | ) |
| (109 | ) |
Other expense, net | (145 | ) |
| (29 | ) |
| (276 | ) |
| (152 | ) |
|
|
|
|
|
|
|
|
Total other expense | (145 | ) |
| (138 | ) |
| (1,011 | ) |
| (261 | ) |
|
|
|
|
|
|
|
|
Income before income taxes | 4,149 |
|
| 3,258 |
|
| 13,842 |
|
| 9,674 |
|
|
|
|
|
|
|
|
|
Income tax provision | 1,100 |
|
| 1,280 |
|
| 5,047 |
|
| 3,724 |
|
|
|
|
|
|
|
|
|
Net income and comprehensive income | $ | 3,049 |
|
| $ | 1,978 |
|
| $ | 8,795 |
|
| $ | 5,950 |
|
|
|
|
|
|
|
|
|
Net income attributable to common stockholders: |
|
|
|
|
|
|
|
Basic | $ | 3,020 |
|
| $ | 607 |
|
| $ | 10,245 |
|
| $ | 1,717 |
|
Diluted | $ | 3,036 |
|
| $ | 1,213 |
|
| $ | 9,530 |
|
| $ | 3,520 |
|
|
|
|
|
|
|
|
|
Net income per share attributable to common stockholders: |
|
|
|
|
|
|
|
Basic | $ | 0.06 |
|
| $ | 0.11 |
|
| $ | 0.44 |
|
| $ | 0.31 |
|
Diluted | $ | 0.05 |
|
| $ | 0.04 |
|
| $ | 0.19 |
|
| $ | 0.12 |
|
|
|
|
|
|
|
|
|
Weighted-average number of shares used in computing net income per share attributable to common stockholders: |
|
|
|
|
|
|
|
Basic | 53,678 |
|
| 5,582 |
|
| 23,232 |
|
| 5,548 |
|
Diluted | 57,553 |
|
| 28,725 |
|
| 50,052 |
|
| 28,705 |
|
| | | | | | | |
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of redeemable convertible preferred stock and stockholders’ equity (deficit) (unaudited)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | Stockholders’ equity (deficit) | |
| Redeemable
convertible
preferred stock | | | Convertible
preferred stock | | | Common stock | | | Common
stock
warrants |
| | Additional
paid-in
capital |
| | Accumu-
lated
deficit |
| | Total
stock-
holders'
equity
(deficit) |
|
(in thousands, except exercise prices) | Shares |
| | Amount |
| | Shares |
| | Amount |
| | Shares |
| | Amount |
| |
Balance as of January 31, 2014 | 17,349 |
| | $ | 46,714 |
| | 6,156 |
| | $ | 8,129 |
| | 7,038 |
| | $ | 1 |
| | $ | 2,334 |
| | $ | — |
| | $ | (23,170 | ) | | $ | (12,706 | ) |
Issuance of series D-3 redeemable convertible preferred stock cash dividend | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | (347 | ) | | — |
| | (347 | ) |
Issuance of common stock cash dividend | — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| (50,000 | ) |
| — |
|
| (50,000 | ) |
Issuance of common stock: | | | | | | | | | | | | | | | | | | | |
Exercise of 2,972 warrants at $0.8008 per share | — |
| | — |
| | — |
| | — |
| | 2,972 |
| | — |
| | (2,334 | ) | | 4,714 |
| | — |
| | 2,380 |
|
Exercise of 1,793 options at $1.3370 per share | — |
| | — |
| | — |
| | — |
| | 1,793 |
| | — |
| | — |
| | 2,397 |
| | — |
| | 2,397 |
|
Conversion of preferred stock to common stock upon initial public offering | (17,349 | ) |
| (42,693 | ) |
| (6,156 | ) |
| (8,129 | ) |
| 32,486 |
|
| 3 |
|
| — |
|
| 50,819 |
|
| — |
|
| 42,693 |
|
Issuance of common stock | — |
|
| — |
|
| — |
|
| — |
|
| 10,465 |
|
| 1 |
|
| — |
|
| 132,586 |
|
| — |
|
| 132,587 |
|
Stock-based compensation | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | 793 |
| | — |
| | 793 |
|
Tax benefit on stock options exercised | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | 2,974 |
| | — |
| | 2,974 |
|
Redeemable convertible preferred stock accretion | — |
| | (4,021 | ) | | — |
| | — |
| | — |
| | — |
| | — |
| | 4,021 |
| | — |
| | 4,021 |
|
Reclassification of series D-3 redeemable convertible preferred stock derivative liability | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | 6,917 |
| | — |
| | 6,917 |
|
Net income | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | — |
| | 8,795 |
| | 8,795 |
|
Balance as of October 31, 2014 | — |
| | $ | — |
| | — |
| | $ | — |
| | 54,754 |
| | $ | 5 |
| | $ | — |
| | $ | 154,874 |
| | $ | (14,375 | ) | | $ | 140,504 |
|
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) |
| | | | | | | |
| Nine months ended October 31, | |
(in thousands) | 2014 |
|
| 2013 |
|
|
|
|
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
Net income | $ | 8,795 |
|
| $ | 5,950 |
|
|
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
Depreciation and amortization | 4,187 |
|
| 3,140 |
|
Loss on revaluation of redeemable convertible preferred stock derivative | 735 |
|
| 109 |
|
Imputed interest on notes payable | — |
|
| 30 |
|
Deferred taxes | 2,026 |
|
| 3,670 |
|
Stock-based compensation | 793 |
|
| 44 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
Restricted cash | — |
|
| 791 |
|
Accounts receivable | (349 | ) |
| (186 | ) |
Inventories | (365 | ) |
| (204 | ) |
Prepaid expenses | (2,124 | ) |
| (230 | ) |
Accounts payable | (1,542 | ) |
| (533 | ) |
Due to trust | — |
|
| (791 | ) |
Accrued compensation | (1,125 | ) |
| (555 | ) |
Accrued liabilities | (540 | ) |
| 1,080 |
|
Income taxes payable | — |
|
| (77 | ) |
Deferred rent | 88 |
|
| 199 |
|
|
|
|
|
Net cash provided by operating activities | 10,579 |
|
| 12,437 |
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
Purchase of property and equipment | (1,477 | ) |
| (1,226 | ) |
Purchase of software and capitalized software development costs | (4,851 | ) |
| (2,735 | ) |
Purchase of other investments | (305 | ) |
| — |
|
|
|
|
|
Net cash used in investing activities | (6,633 | ) |
| (3,961 | ) |
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
Repayment of notes payable | — |
|
| (1,500 | ) |
Dividend payments | (50,347 | ) |
| — |
|
Proceeds from initial public offering, net of payments for offering costs | 132,587 |
|
| — |
|
Proceeds from exercise of common stock options | 2,397 |
|
| 232 |
|
Proceeds from exercise of common stock warrants | 2,380 |
|
| 17 |
|
Tax benefit from exercise of common stock options | 2,974 |
|
| — |
|
|
|
|
|
Net cash provided by (used in) financing activities | 89,991 |
|
| (1,251 | ) |
|
|
|
|
Increase in cash and cash equivalents | 93,937 |
|
| 7,225 |
|
|
|
|
|
Beginning cash and cash equivalents | 13,917 |
|
| 5,905 |
|
|
|
|
|
Ending cash and cash equivalents | $ | 107,854 |
|
| $ | 13,130 |
|
|
|
|
|
Supplemental disclosures of non-cash investing and financing activities: |
|
|
|
Conversion of preferred stock to common stock | $ | 50,822 |
|
| $ | — |
|
Preferred stock accretion | 4,021 |
|
| 925 |
|
Reclassification of series D-3 redeemable convertible preferred stock derivative liability | 6,917 |
|
| — |
|
Common stock warrants exercised | 2,334 |
|
| 35 |
|
Series D-3 redeemable convertible preferred stock dividend | — |
|
| 519 |
|
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 1. Summary of business and significant accounting policies
HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002, and was organized to offer a full range of innovative solutions for managing health care accounts (Health Savings Accounts, Health Reimbursement Arrangements, and Flexible Spending Accounts) for health plans, insurance companies, and third-party administrators.
Principles of consolidation—The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, First HSA, LLC, First Horizon MSaver, Inc., HEQ Insurance Services, Inc., and HealthEquity Advisors, LLC (collectively referred to as the "Company"). All significant intercompany balances and transactions have been eliminated.
Basis of presentation—The accompanying condensed consolidated financial statements as of October 31, 2014 and for the three and nine months ended October 31, 2014 and 2013 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's final prospectus (dated July 30, 2014) filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933 on August 1, 2014.
The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Initial public offering—On August 5, 2014, the Company consummated its initial public offering ("IPO") and issued and sold 10,465,000 shares of its common stock at a public offering price of $14.00 per share, less the underwriters' discount. The Company received net proceeds of approximately $132.6 million after deducting underwriters' discounts and commissions of approximately $10.2 million and other offering expenses payable by the Company of approximately $3.7 million. The underwriting discounts and commissions and other offering expenses were recorded as an offset against the IPO proceeds in additional paid-in capital upon the closing of the IPO on August 5, 2014.
Capital structure—On July 14, 2014, the Company's board of directors approved an amended and restated certificate of incorporation, pursuant to which the total number of shares of all classes of capital stock that the Company is authorized to issue is 1,000,000,000 shares, including 900,000,000 shares of common stock and 100,000,000 shares of preferred stock, par value $0.0001 per share. The amended and restated certificate of incorporation was filed with the Secretary of State of the State of Delaware and became effective on August 5, 2014.
On July 14, 2014, the Company's board of directors declared a cash dividend in an aggregate amount of $50.0 million on shares of the Company's common stock outstanding on August 4, 2014 (after giving effect to the conversion of all outstanding convertible preferred stock and redeemable convertible preferred stock into shares of common stock). The terms of each of the Company's stock plans, including the 2003 Director Stock Plan, 2003 Stock Plan, 2005 Stock Plan, 2006 Stock Plan, 2009 Stock Plan and the 2014 Equity Incentive Plan (the "Incentive Plan") requires an adjustment to outstanding stock options to prevent dilution of the holders’ interests as a result of the foregoing special dividend. Accordingly, the Company's board of directors approved an adjustment to reduce the exercise price of each of the stock options outstanding as of the record date, August 4, 2014, for the dividend by $1.00.
As of the close of business on August 4, 2014, all of the Company's redeemable convertible preferred stock and convertible preferred stock converted into 32,486,588 shares of common stock.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 1. Summary of business and significant accounting policies (continued)
Recent accounting pronouncements—On May 28, 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in GAAP when it becomes effective. The new standard is effective for our annual and interim reporting periods beginning February 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on the consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on the ongoing financial reporting.
Revision of previously issued financial statements—In the three months ended October 31, 2014, the Company identified an error that originated in the three months ended July 31, 2014. This error was caused by using an incorrect fair value amount in calculating the windfall tax benefit for a portion of the vested options exercised during the period. The adjustment increased prepaid expenses and additional paid-in capital by approximately $1.0 million. The error also decreased cash provided by operating activities by $1.0 million and increased cash provided by financing activities by the same amount. The error had no impact to the condensed consolidated statement of operations and comprehensive income. The correction has been properly reflected in both the condensed consolidated balance sheets as of October 31, 2014, and in the condensed consolidated statements of cash flows for the nine months ended October 31, 2014. The Company determined this error did not materially impact the July 31, 2014 financial statements nor the October 31, 2014 financial statements; however, in order to correctly present the financial statements, the July 31, 2014 financial statements will be revised the next time the financial statements are filed to reflect this correction.
Note 2. Net income per share attributable to common stockholders
The Company computes net income per share of common stock in conformity with the two-class method required for participating securities. The Company considers its series D-3 redeemable convertible preferred stock to be participating securities as the holders of the preferred stock were entitled to receive a dividend in the event that a dividend is paid on common stock. The following table sets forth the computation of basic and diluted net income per share attributable to common stockholders:
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 2. Net income per share attributable to common stockholders (continued)
|
| | | | | | | | | | | | | | | | |
(in thousands, except per share data) |
| Three months ended October 31, | |
| Nine months ended October 31, | |
| 2014 |
|
| 2013 |
|
| 2014 |
|
| 2013 |
|
Numerator (basic and diluted): |
|
|
|
|
|
|
|
|
Net income |
| $ | 3,049 |
|
| $ | 1,978 |
|
| $ | 8,795 |
|
| $ | 5,950 |
|
Add back (deduction): accretion of redeemable convertible preferred stock |
| — |
|
| (245 | ) |
| 4,021 |
|
| (925 | ) |
Less: dividend on redeemable convertible preferred stock and dividend on convertible preferred stock |
| (21 | ) |
| (650 | ) |
| (1,286 | ) |
| (1,951 | ) |
Less: undistributed income attributed to redeemable convertible preferred stockholders |
| (8 | ) |
| (476 | ) |
| (1,285 | ) |
| (1,357 | ) |
Net income attributable to common stockholders for basic earnings per share |
| $ | 3,020 |
|
| $ | 607 |
|
| $ | 10,245 |
|
| $ | 1,717 |
|
Add back: dividend of redeemable convertible preferred stock |
| 15 |
|
| 241 |
|
| 1,286 |
|
| 723 |
|
Add back (deduction): accretion on redeemable convertible preferred stock and dividend on convertible preferred stock |
| — |
|
| 75 |
|
| (4,021 | ) |
| 284 |
|
Add back: series D-3 derivative liability revaluations |
| — |
|
| — |
|
| 735 |
|
| — |
|
Add back: adjustment to undistributed income attributed to redeemable convertible preferred stockholders |
| 1 |
|
| 290 |
|
| 1,285 |
|
| 796 |
|
Net income attributable to common stockholders for diluted earnings per share |
| $ | 3,036 |
|
| $ | 1,213 |
|
| $ | 9,530 |
|
| $ | 3,520 |
|
|
|
|
|
|
|
|
|
|
Denominator (basic): |
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding |
| 53,678 |
|
| 5,582 |
|
| 23,232 |
|
| 5,548 |
|
Denominator (diluted): |
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding |
| 53,678 |
|
| 5,582 |
|
| 23,232 |
|
| 5,548 |
|
Effect of potential dilutive securities: |
|
|
|
|
|
|
|
|
Weighted-average dilutive effect of stock options |
| 2,944 |
|
| 1,156 |
|
| 3,290 |
|
| 1,168 |
|
Weighted-average dilutive effect of common shares from stock warrants |
| 3 |
|
| 2,579 |
|
| 1,634 |
|
| 2,581 |
|
Dilutive effect from preferred stock assuming conversion |
| 928 |
|
| 19,408 |
|
| 21,896 |
|
| 19,408 |
|
Weighted-average common shares outstanding |
| 57,553 |
|
| 28,725 |
|
| 50,052 |
|
| 28,705 |
|
Net income per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
Basic |
| $ | 0.06 |
|
| $ | 0.11 |
|
| $ | 0.44 |
|
| $ | 0.31 |
|
Diluted |
| $ | 0.05 |
|
| $ | 0.04 |
|
| $ | 0.19 |
|
| $ | 0.12 |
|
For the three months ended October 31, 2014 and 2013, approximately 322,000 and 14.5 million shares, respectively, attributable to outstanding series D-3 redeemable convertible preferred stock, series C redeemable convertible preferred stock and stock options were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 2. Net income per share attributable to common stockholders (continued)
For the nine months ended October 31, 2014 and 2013, approximately 164,000 and 14.4 million shares, respectively, attributable to outstanding series D-3 redeemable convertible preferred stock, series C redeemable convertible preferred stock and stock options were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
Note 3. Property and equipment
Property and equipment consisted of the following as of October 31, 2014 and January 31, 2014:
|
| | | | | | | | |
(in thousands) |
| October 31, 2014 |
|
| January 31, 2014 |
|
Leasehold improvements |
| $ | 482 |
|
| $ | 329 |
|
Furniture and fixtures |
| 1,317 |
|
| 1,094 |
|
Computer equipment |
| 4,176 |
|
| 3,075 |
|
Property and equipment, gross |
| 5,975 |
|
| 4,498 |
|
Accumulated depreciation |
| (3,287 | ) |
| (2,506 | ) |
Property and equipment, net |
| $ | 2,688 |
|
| $ | 1,992 |
|
Depreciation expense for the three and nine months ended October 31, 2014 was $290,000 and $776,000, respectively, and $215,000 and $562,000 for the three and nine months ended October 31, 2013, respectively.
Note 4. Intangible assets and goodwill
During the three and nine months ended October 31, 2014, the Company capitalized software development costs of $1.4 million and $3.8 million, respectively, and $343,000 and $948,000 for the three and nine months ended October 31, 2013, respectively, related to significant enhancements and upgrades to its proprietary system.
The gross carrying amount and associated accumulated amortization of intangible assets is as follows as of October 31, 2014 and January 31, 2014:
|
| | | | | | | | |
(in thousands) |
| October 31, 2014 |
|
| January 31, 2014 |
|
Amortized intangible assets: |
|
|
|
|
Capitalized software development costs |
| $ | 9,073 |
|
| $ | 5,290 |
|
Software |
| 4,532 |
|
| 3,351 |
|
Acquired intangible member assets |
| 24,563 |
|
| 24,563 |
|
Intangible assets, gross |
| 38,168 |
|
| 33,204 |
|
Accumulated amortization |
| (11,918 | ) |
| (8,513 | ) |
Intangible assets, net |
| $ | 26,250 |
|
| $ | 24,691 |
|
During the three and nine months ended October 31, 2014, the Company incurred and expensed a total of $1.2 million and $3.2 million, respectively, and $541,000 and $1.7 million for the three and nine months ended October 31, 2013, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software.
Amortization expense for the three and nine months ended October 31, 2014 was $1.3 million and $3.4 million, respectively, and $936,000 and $2.6 million for the three and nine months ended October 31, 2013, respectively.
All of the Company’s goodwill was generated from the acquisition of First Horizon MSaver, Inc. on August 11, 2011. There have been no changes to the goodwill carrying value during the three and nine months ended October 31, 2014 and 2013.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 5. Commitments and contingencies
The Company’s principal commitments and contingencies consist of a processing services agreement with a vendor, and obligations for office space, data storage facilities, equipment and certain maintenance agreements under long-term, non-cancelable operating leases. These commitments as of January 31, 2014 are disclosed in the Company’s consolidated financial statements included in its final prospectus (dated July 30, 2014) filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933 on August 1, 2014, and did not change materially during the three and nine months ended October 31, 2014 except for the following:
In March 2014, the Company modified its corporate office lease to expand its existing space for an additional commitment of $1.1 million over the term of the original lease.
Lease expense for office space for the three and nine months ended October 31, 2014 was $374,000 and $944,000, respectively, and $237,000 and $672,000 for the three and nine months ended October 31, 2013, respectively. Expense for other lease agreements for the three and nine months ended October 31, 2014 was $67,000 and $166,000, respectively, and $62,000 and $127,000 for the three and nine months ended October 31, 2013, respectively.
Note 6. Income taxes
The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three and nine months ended October 31, 2014, the Company recorded a provision for income taxes of $1.1 million and $5.0 million, respectively. The resulting effective tax rate was 26.5% and 36.5%, compared with an effective tax rate of 39.3% and 38.5% for the three and nine months ended October 31, 2013, respectively. For the three and nine months ended October 31, 2014, the net impact of discrete tax items caused a 12.1% and 3.1% decrease to the effective tax rate primarily due to the recognition of research and development tax credits, book stock compensation expense on stock options vesting upon the Company's initial public offering treated as a discrete event, and the impact of changes in estimated annual tax rates. For the three and nine months ended October 31, 2013, the net impact of discrete tax items was not significant. The effective tax rate decreased over the same period last year primarily due to discrete tax items, offset by an increase in permanent tax items in relation to income before income taxes, including expiration of the federal research and development tax credits as of December 31, 2013.
As of October 31, 2014 and January 31, 2014, the Company’s total gross unrecognized tax benefit was $229,000 and $256,000, respectively. As a result of Accounting Standards Update No. 2013-11, certain unrecognized tax benefits have been netted against their related deferred tax assets. As a result, the unrecognized tax benefit recorded as of October 31, 2014 and January 31, 2014 was $53,000 and $47,000, respectively. Substantially all of the gross unrecognized tax benefit, if recognized, would affect the Company’s effective tax rate. The Company anticipates a decrease of $6,000 in total gross unrecognized tax benefits within 12 months of the reporting date related to an uncertain tax position on research and development credits claimed for which a lapse of the applicable statute of limitations is expected.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 7. Redeemable convertible preferred stock and convertible preferred stock
In connection with the Company's IPO, all outstanding shares of the Company's convertible preferred stock and redeemable convertible preferred stock converted into 32,486,588 shares of common stock. In accordance with their respective terms, shares of the series A and series B convertible preferred stock and D-3 redeemable convertible preferred stock converted into shares of common stock on a 1:1 basis, shares of series C redeemable and convertible preferred stock converted into shares of common stock on a 1:1.38 basis, shares of the series D-1 redeemable convertible preferred stock converted into shares of common stock on a 1:2 basis, and shares of the series D-2 redeemable convertible preferred stock converted into shares of common stock on a 1:2.27 basis. As a result, as of August 4, 2014, amounts associated with the convertible preferred stock and redeemable convertible preferred stock were reclassified to additional paid-in capital, and no amounts were outstanding as of October 31, 2014.
As of January 31, 2014, the Company had outstanding shares of series A and B convertible preferred stock and series C, D-1, D-2, and D-3 redeemable convertible preferred stock. Redeemable convertible preferred stock and convertible preferred stock as of January 31, 2014 consisted of the following:
|
| | | | | | | | | | | | | | |
| | Shares | | | | | |
Series | | Authorized |
| | Issued and
outstanding |
| | Liquidation
preference |
| | Carrying
value |
|
Redeemable convertible preferred stock: | | | | | | | | |
Series C | | 6,773 |
| | 6,751 |
| | $ | 22,533 |
| | $ | 22,232 |
|
Series D-1 | | 9,000 |
| | 5,835 |
| | 8,464 |
| | 8,340 |
|
Series D-2 | | 3,200 |
| | 440 |
| | 719 |
| | 709 |
|
Series D-3 | | 7,500 |
| | 4,323 |
| | 11,412 |
| | 15,433 |
|
Total redeemable convertible preferred stock | | 26,473 |
| | 17,349 |
| | $ | 43,128 |
| | $ | 46,714 |
|
Convertible preferred stock: | | | | | | | | |
Series A | | 2,000 |
| | 2,000 |
| | $ | 3,291 |
| | $ | 2,000 |
|
Series B | | 4,738 |
| | 4,156 |
| | 9,473 |
| | 6,129 |
|
Total convertible preferred stock | | 6,738 |
| | 6,156 |
| | $ | 12,764 |
| | $ | 8,129 |
|
Note 8. Common stock warrants
In conjunction with a rights equalization agreement, the Company issued warrants to series A convertible preferred stockholders to purchase 150,000 shares of its common stock for $1.00 per share, The warrants were exercisable through November 2015, of which 26,000 were exercised with 124,000 outstanding as of January 31, 2014. The 124,000 warrants outstanding as January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $51,000 at the date of issuance.
In conjunction with the issuance of the series B convertible preferred stock, warrants to purchase 400,000 shares of common stock with an exercise price of $1.00 per share were granted to series B convertible preferred stockholders. The warrants were exercisable through February 2014, of which 50,000 were exercised with 350,000 outstanding as of January 31, 2014. Of the 350,000 warrants outstanding as of January 31, 2014, 340,000 were exercised, and 10,000 were forfeited during the nine months ended October 31, 2014. The warrants had a fair market value of $44,000 at the date of issuance.
The Company issued warrants to purchase an additional 200,000 shares of common stock to series B convertible preferred stockholders with an exercise price of $1.00 per share. The warrants were exercisable through September 2015, of which 5,000 were exercised with 195,000 outstanding as of January 31, 2014. The 195,000 warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $66,000 at the date of issuance.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 8. Common stock warrants (continued)
In conjunction with the issuance of the series C redeemable convertible preferred stock, the Company issued detachable warrants to purchase 600,000 shares of common stock with an exercise price of $1.50 per share to series C redeemable convertible preferred stockholders. The warrants were exercisable through August 2016, of which 10,000 were exercised with 590,000 outstanding as of January 31, 2014. The 590,000 warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $339,000 at the date of issuance. The Company issued warrants to purchase an additional 1.0 million shares of common stock to series C redeemable convertible preferred stockholders with an exercise price of $0.01 per share. The warrants were exercisable through May 2017, of which 4,000 were exercised with 1.0 million outstanding as of January 31, 2014. The 1.0 million warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $1.6 million at the date of issuance.
In conjunction with the issuance of the series D-1 redeemable convertible preferred stock, the Company issued detachable warrants to purchase 400,000 shares of common stock with an exercise price of $2.00 per share. The warrants were exercisable upon the option of the stockholder through August 2018, of which 400,000 were outstanding as of January 31, 2014. The 400,000 warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014.
In conjunction with the issuance of the series D-3 redeemable convertible preferred stock, warrants to purchase 966,000 shares of common stock with an exercise price of $0.01 per share were granted to series D-3 redeemable convertible preferred stockholders. The warrants were exercisable through August 2021, of which 767,000 were exercised with 199,000 outstanding as of January 31, 2014. The warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a value of $1.7 million at the date of issuance.
As a result of the foregoing, as of October 31, 2014, there were no warrants outstanding.
Note 9. Stock options
On January 30, 2014, the Company’s board of directors approved, and the Company adopted, the Incentive Plan providing for the issuance of stock options to the directors and employees of the Company to purchase up to an aggregate of 600,000 shares of common stock. No stock options were issued to directors of the Company from the Incentive Plan as of January 31, 2014.
In July 2014, the Company's board of directors voted to increase the shares of common stock reserved under the Incentive Plan by 2,000,000 shares from 600,000 shares of common stock to 2,600,000 shares of common stock. In addition, the board of directors voted to provide that the number of shares of common stock reserved for issuance under the Incentive Plan will automatically increase on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of October 31, 2014, 631,000 shares were available for grant under the Incentive Plan.
Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonstatutory stock options. Incentive stock options may be granted only to Company employees. Nonstatutory stock options may be granted to Company employees, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Any stock options that are forfeited or that expire are returned to the Incentive Plan.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 9. Stock Options (continued)
During the three and nine months ended October 31, 2014, the Company granted 56,000 and 487,500 time-based stock options to certain directors and key employees, respectively, of which 56,000 and 405,000 vest over a period of 4 years and 82,500 of which vest on January 31, 2015. In addition, during the three and nine months ended October 31, 2014, the Company granted 58,000 and 1.4 million performance-based stock options, respectively, to certain key employees under the Incentive Plan, which vest upon the achievement of certain performance criteria. The performance-based stock options vest upon the attainment of the following performance criteria: (a) 10% of the stock options vest upon attainment of at least $34.5 million in Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") for the fiscal year 2016, (b) 20% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 30% for the fiscal year 2017, (c) 30% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 30% for fiscal year 2018, and (d) 40% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 25% for fiscal year 2019.
A summary of stock option activity is as follows:
|
| | | | | | | | | | | | | | | |
|
| Outstanding stock options | |
(in thousands, except for exercise prices and term) |
| Number of
options |
|
| Range of
exercise
prices |
| Weighted-
average
exercise
price |
|
| Weighted-
average
contractual
term
(in years) |
| Aggregate
intrinsic
value |
|
Outstanding as of January 31, 2014 |
| 6,369 |
|
| $1.10 - 4.50 |
| $ | 1.77 |
|
| 6.34 |
| $ | 14,621 |
|
Granted |
| 1,946 |
|
| $14.00 - 18.93 |
| $ | 14.29 |
|
|
|
|
|
Exercised |
| (1,793 | ) |
| $0.50 - 2.50 |
| $ | 1.34 |
|
|
|
|
|
Forfeited |
| (169 | ) |
| $1.25 - 14.00 |
| $ | 9.97 |
|
|
|
|
|
Outstanding as of October 31, 2014 |
| 6,353 |
|
| $0.10 - 18.93 |
| $ | 4.79 |
|
| 7.03 |
| $ | 99,157 |
|
A summary regarding non-vested and exercisable stock options is as follows:
|
| | | | | | | | | | | | | | | | | | | | |
|
| Non-vested stock options | |
| Exercisable stock options | |
(in thousands, except for exercise prices and term) |
| Number of
shares |
|
| Weighted-
average
grant date
fair value |
|
| Number of
shares |
|
| Weighted-
average
exercise
price |
|
| Weighted-
average
contractual
term
(in years) |
| Aggregate
intrinsic
value |
|
Balance as of January 31, 2014 |
| 2,812 |
|
| $ | 0.26 |
|
| 3,557 |
|
| $ | 1.30 |
|
| 5.03 |
| $ | 9,835 |
|
Granted |
| 1,946 |
|
| $ | 5.25 |
|
| — |
|
| $ | — |
|
|
|
|
|
Vesting |
| (2,216 | ) |
| $ | 0.22 |
|
| 2,216 |
|
| $ | 1.25 |
|
|
|
|
|
Exercised |
| — |
|
| $ | — |
|
| (1,793 | ) |
| $ | 1.34 |
|
|
|
|
|
Forfeited/expired |
| (164 | ) |
| $ | 3.61 |
|
| (5 | ) |
| $ | 2.25 |
|
|
|
|
|
Balance as of October 31, 2014 |
| 2,378 |
|
| $ | 4.15 |
|
| 3,975 |
|
| $ | 0.80 |
|
| 5.59 |
| $ | 77,916 |
|
Vested and expected to vest as of October 31, 2014 |
|
|
|
|
| 4,772 |
|
| $ | 2.01 |
|
| 6.17 |
| $ | 87,742 |
|
The aggregate intrinsic value in the tables above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 9. Stock Options (continued)
The total intrinsic value of stock options exercised in the three and nine months ended October 31, 2014 was $479,000 and $8.4 million, respectively, and $20,000 and $155,000 for the three and nine months ended October 31, 2013, respectively.
The key input assumptions that were utilized in the valuation of the stock options granted during the three and nine months ended October 31, 2014 and 2013 are as follows:
|
| | | | | | | | | | | | |
|
| Three months ended October 31, | |
| Nine months ended October 31, | |
|
| 2014 |
|
| 2013 |
|
| 2014 |
|
| 2013 |
|
Expected dividend yield |
| — | % |
| — | % |
| — | % |
| — | % |
Expected stock price volatility |
| 32.9 | % |
| 31.3 | % |
| 32.9 | % |
| 31.3 | % |
Risk-free interest rate |
| 1.93 | % |
| 0.67 | % |
| 1.93% - 2.24% |
|
| 0.35% - 0.67% |
|
Expected life of options |
| 6.25 years |
|
| 3 years |
|
| 6.25 years |
|
| 3 years |
|
The determination of the fair value of stock options on the date of grant using an option pricing model is affected by the Company's stock price as well as assumptions regarding a number of complex and subjective variables. Expected volatility is determined using weighted average volatility of publicly traded peer companies. The Company expects that it will begin using the weighted average volatility of peer publicly traded companies in addition to its own historical volatility, as that history grows over time. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations. The Company uses the "simplified" method to estimate expected term as determined under Staff Accounting Bulletin No. 110 due to the lack of option exercise history as a public company.
As of October 31, 2014, the weighted-average vesting period of non-vested awards expected to vest approximates 3.5 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods approximates $1.4 million.
During the three and nine months ended October 31, 2014, the Company recorded compensation expense of $325,000 and $793,000, respectively, of which $0 and $436,000 related to the performance-based options based on the Company's probability assessment of attaining its Adjusted EBITDA target and consummation of the IPO.
Note 10. Fair value
A derivative liability was recorded related to the Company’s series D-3 redeemable convertible preferred stock due to stated features allowing for redemption equal to the greater of the fair value per share of series D-3 redeemable convertible preferred stock, or the liquidation preference per share of series D-3 redeemable convertible preferred stock. The derivative instrument is recorded at its fair value, using an option pricing model, and is adjusted to fair value as of the end of each reporting period. Changes in the fair value of derivative instruments are recognized currently in the condensed consolidated financial statements. The Company has classified this derivative financial instrument as Level 3 in the fair value hierarchy. The Company continued to record adjustments to the fair value of the derivative liability until March 31, 2014, at which time the Company modified the terms of the series D-3 redeemable convertible preferred stock. As a result of the modifications, the Company reclassified the aggregate fair value of the liability to additional paid-in capital.
The following table includes a roll forward of the amounts for the three and nine months ended October 31, 2014 and 2013 for instruments classified within Level 3. The classification within Level 3 is based upon significance of the unobservable inputs to the overall fair value measurement.
HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements (unaudited)
Note 10. Fair value (continued)
|
| | | | | | | | | | | | | | | | |
|
| Three months ended October 31, | |
| Nine months ended October 31, | |
(in thousands) |
| 2014 |
|
| 2013 |
|
| 2014 |
|
| 2013 |
|
Balance at beginning of period |
| $ | — |
|
| $ | 818 |
|
| $ | 6,182 |
|
| $ | 818 |
|
Loss on revaluation |
| — |
|
| 109 |
|
| 735 |
|
| 109 |
|
Elimination of liability due to removal of FMV provision |
| — |
|
| — |
|
| (6,917 | ) |
| — |
|
Balance at end of period |
| $ | — |
|
| $ | 927 |
|
| $ | — |
|
| $ | 927 |
|
The following table summarizes the significant quantitative inputs and assumptions used for items categorized in Level 3 of the fair value hierarchy as of January 31, 2014:
Series D-3 redeemable convertible preferred stock derivative liability
|
| | | | |
|
| January 31, 2014 |
|
Market value of common stock on measurement date |
| $ | 4.06 |
|
Projected exercise price |
| $ | 2.64 |
|
Risk-free interest rate |
| 0.06 | % |
Expected lives |
| 180 days |
|
Expected volatility |
| 25.2 | % |
Probability of liquidation event |
| — | % |
There are no other financial instruments that are considered Level 1 or Level 2 as of October 31, 2014 and January 31, 2014.
Note 11. Related party transactions
The Company had entered into a consulting agreement with a company owned by the President and Chief Executive Officer of the Company. For the three and nine months ended October 31, 2014 amounts paid to this company under the terms of the consulting agreement were $0 and $162,000, respectively, and $81,000 and $369,000 for the three and nine months ended October 31, 2013, respectively. In connection with the consummation of the Company's IPO, this consulting agreement was terminated.
Item 2. Management’s discussion and analysis of financial condition and results of operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning market opportunity, our future financial and operating results, investment strategy, sales and marketing strategy, management’s plans, beliefs and objectives for future operations, technology and development, economic and industry trends or trend analysis, expectations about seasonality, opportunity for portfolio purchases, use of non-GAAP financial measures, operating expenses, anticipated income tax rates, capital expenditures, cash flows and liquidity. These statements are based on the beliefs and assumptions of our management based on information currently available to us. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk factors” included under Part II, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such events.
Overview
We are a leader and an innovator in the high-growth category of technology-enabled services platforms that empower consumers to make healthcare saving and spending decisions. Our platform provides an ecosystem where consumers can access their tax-advantaged healthcare savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives, and make educated investment choices to grow their tax-advantaged healthcare savings.
The core of our ecosystem is the health savings account, or HSA, a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis. We are the integrated HSA platform for 20 of the 50 largest health plans in the country, a number of which are among 28 Blue Cross and Blue Shield health plans in 26 states, and more than 25,000 employer clients, including industry leaders such as American Express Company, Dow Corning Corporation, eBay, Inc., Google, Inc., Intermountain Healthcare and Kohl’s Corporation. Through our Network Partners, we have the potential to reach over 55 million consumers, representing approximately 30% of the under-age 65 privately insured population in the United States.
Since our inception in 2002, we have been committed to developing technology solutions that empower healthcare consumers. In 2003, we began offering live 24/7/365 consumer support from health saving and spending experts. In 2005, we integrated HSAs with our first Health Plan Partner, and in 2006, we were authorized to act as an HSA custodian by the U.S. Department of the Treasury. In 2009, we integrated HSAs with multiple health plans of a single large employer, began delivering integrated wellness incentives through an HSA, and partnered with a private health insurance exchange as its preferred HSA partner. In 2011, we integrated HSAs, reimbursement arrangements, or RAs, and investment accounts on one website, and in 2013, we began delivering HSA-specific investment advice online.
Our customers include individuals, employers of all sizes and health plans. We refer to our individual customers as our members, all of our health plan customers as our Health Plan Partners and our employer customers with more than 1,000 employees as our Employer Partners. Our Health Plan Partners and Employer Partners collectively constitute our Network Partners.
We generate revenue primarily from three sources: account fees, custodial fees and card fees. We generate account fee revenue by providing monthly account services on our platform, primarily through multi-year contracts
with our Network Partners that are typically three to five years in duration. We generate custodial fee revenue from interest we earn on cash assets under management, or AUM, deposited with our FDIC-insured custodial depository bank partners, and recordkeeping fees we earn from mutual funds in which our members invest on a self-directed basis. We also generate payment card fee revenue from interchange fees that we earn on payments that our members make using our physical and virtual payment cards.
Key factors affecting our performance
We believe that our performance and future success are driven by a number of factors, including those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See the section entitled “Risk factors.”
Structural change in U.S. private health insurance
Substantially all of our revenue is derived from healthcare-related saving and spending by consumers, which is impacted by changes affecting the broader healthcare industry. The healthcare industry has changed significantly in recent years, and we expect that significant changes will continue to occur that will result in increased participation in high deductible health plans that are eligible to be coupled with HSAs, or HSA Plans, and other consumer-centric health plans. In particular, we believe that the implementation of the Patient Protection and Affordable Care Act of 2010, or PPACA, over the remainder of this decade, continued growth in healthcare costs, and related factors will spur HSA Plan and HSA growth; however, the timing and impact of these and other developments in the healthcare industry are difficult to predict.
Attracting and penetrating network partners
We created our business model to take advantage of the changing dynamics of the U.S. private health insurance market. Our model is based on a business-to-business-to-consumer, or B2B2C, distribution strategy, meaning we rely on our Employer Partners and Health Plan Partners to reach potential members to increase the number of HSAs for which we serve as custodian, which we refer to as our HSA Members. Our success depends in large part on our ability to further penetrate our existing Network Partners by adding new members from these partners and adding new Network Partners.
Our innovative technology platform
We believe that innovations incorporated in our technology that enable consumers to make healthcare saving and spending decisions differentiate us from our competitors and drive our growth in revenue, HSA Members, Network Partners and AUM. Similarly, these innovations underpin our ability to provide a differentiated consumer experience in a cost-effective manner. For example, we are currently undertaking a significant update of our proprietary platform’s architecture, which will allow us to decrease our maintenance spending and increase our budget for innovation initiatives. As part of this project, we are also investing in improvements in our transaction processing capabilities and related platform infrastructure to support continued account and transaction growth. We intend to continue to invest aggressively in our technology development to enhance our platform’s capabilities and infrastructure.
Our “Purple” culture
The new healthcare consumer needs education and advice delivered by people as well as technology. We believe that our team-oriented customer-focused culture, which we call “Purple,” is a significant factor in our ability to attract and retain customers and to nimbly address opportunities in the rapidly changing healthcare sector. We make significant efforts to promote and foster Purple within our workforce. We invest in and intend to continue to invest in human capital through technology-enabled training, career development and advancement opportunities. We regularly measure the success of these efforts, particularly in the context of rapid growth.
Interest rates
As a non-bank custodian, we contract with FDIC-insured custodial depository bank partners to hold cash AUM, and we generate a significant portion of our total revenue from fees we charge based on interest rates offered to us by these partners. These contracts are long-term, substantially reducing our exposure to short-term fluctuations in interest rates. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the interest rate margins available to us and thus the size of the custodial fees we can realize. Conversely, a sustained increase in prevailing interest rates would present us with an opportunity to increase our interest rate margins. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Our competition and industry
Our direct competitors are HSA custodians, of which there are over 2,200 currently competing in the market. These are primarily state or federally chartered banks and other financial institutions for which we believe technology-based healthcare services are not a core business. Certain of our direct competitors have chosen to exit the market despite increased demand for these services. This has created, and we believe will continue to create, opportunities for us to leverage our technology platform and capabilities to increase our market share. However, some of our direct competitors are in a position, should they choose, to devote more resources to the development, sale and support of their products and services than we have at our disposal. In addition, numerous indirect competitors, including benefits administration technology and service providers, partner with banks and other HSA custodians to compete with us. Our Health Plan Partners may also choose to offer technology-based healthcare services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
Regulatory change
Federal law and regulations, including the PPACA, IRS regulations, labor law and public health regulations that govern the provision of health insurance and are the foundation for tax-advantaged healthcare saving and spending through HSAs and RAs, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.
Key financial and operating metrics
Our management regularly reviews a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
HSA members
The following table sets forth our HSA Members as of the periods indicated:
|
| | | | | | | | | | | | |
|
| October 31, 2014 |
|
| October 31, 2013 |
|
| % Change |
|
| January 31, 2014 |
|
HSA Members |
| 1,108,533 |
|
| 759,736 |
|
| 46 | % |
| 967,710 |
|
Average HSA Members - Year-to-date |
| 1,040,531 |
|
| 717,021 |
|
| 45 | % |
| 747,182 |
|
Average HSA Members - Quarter-to-date |
| 1,090,516 |
|
| 748,918 |
|
| 46 | % | | |
We define an HSA Member as an HSA for which we serve as custodian. Tracking the number of our HSA Members is critical because our account fee revenue is driven by the administrative fees we charge per account.
The number of our HSA Members increased by approximately 349,000, or 46%, from October 31, 2013 to October 31, 2014, and by approximately 216,000, or 40%, from October 31, 2012 to October 31, 2013.
The increase in the number of our HSA Members in these periods was driven by the addition of new Network Partners and further penetration into existing Network Partners.
Assets under management
The following table sets forth our AUM as of the periods indicated:
|
| | | | | | | | | | | | | | | | | | | |
(in thousands, except percentages) |
| October 31, 2014 |
|
| October 31, 2013 |
|
| $ Change |
|
| % Change |
|
| January 31, 2014 |
|
Cash AUM |
| $ | 1,578,814 |
|
| $ | 1,146,138 |
|
| $ | 432,676 |
|
| 38 | % |
| $ | 1,442,336 |
|
Investment AUM |
| 256,791 |
|
| 151,663 |
|
| 105,128 |
|
| 69 | % |
| 182,614 |
|
Total AUM |
| $ | 1,835,605 |
|
| $ | 1,297,801 |
|
| $ | 537,804 |
|
| 41 | % |
| $ | 1,624,950 |
|
Average daily cash AUM |
| $ | 1,505,659 |
|
| $ | 1,109,237 |
|
| $ | 396,422 |
|
| 36 | % |
| $ | 1,137,825 |
|
We define AUM as our custodial assets under management. Our AUM, which is our members' assets under management, consists of the following components: (1) cash deposit AUM which are deposits with our FDIC-insured custodial depository bank partners, (2) Cash AUM invested in an annuity contract with our insurance company partner and (3) members' investments in mutual funds through our custodial investment fund partner. Measuring our AUM is important because our custodial fee revenue is determined by the applicable account yields and average daily AUM balances.
Our AUM increased by $537.8 million, or 41%, from October 31, 2013 to October 31, 2014. Our AUM increased by $367.9 million, or 40%, from October 31, 2012 to October 31, 2013. The increase in AUM in these periods was driven by additional AUM from our existing HSA Members and new AUM from new HSA Members added during the fiscal year.
Adjusted EBITDA
The following table sets forth our Adjusted EBITDA:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended October 31, | |
|
|
|
|
| Nine months ended October 31, | |
|
|
|
|
(in thousands, except percentages) | 2014 |
|
| 2013 |
|
| $ Change |
|
| % Change |
|
| 2014 |
|
| 2013 |
|
| $ Change |
|
| % Change |
|
Adjusted EBITDA | $ | 6,065 |
|
| $ | 4,561 |
|
| $ | 1,504 |
|
| 33 | % |
| $ | 19,736 |
|
| $ | 13,036 |
|
| $ | 6,700 |
|
| 51 | % |
We define Adjusted EBITDA, which is a non-GAAP financial metric, as adjusted earnings before interest, taxes, depreciation and amortization and certain other non-cash statement of operations items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses, and serves as a basis for comparison against other companies in our industry.
Our Adjusted EBITDA increased by $1.5 million, or 33%, from $4.6 million for the three months ended October 31, 2013 to $6.1 million for the three months ended October 31, 2014. The increase in Adjusted EBITDA was driven by the overall growth of our business, including a $898,000, or 26%, increase in income from operations.
Our Adjusted EBITDA increased by $6.7 million, or 51%, from $13.0 million for the nine months ended October 31, 2013 to $19.7 million for the nine months ended October 31, 2014. The increase in Adjusted EBITDA was driven by the overall growth of our business, including a $4.9 million, or 50%, increase in income from operations.
Our use of Adjusted EBITDA has limitations as an analytical tool, and it should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
The following table presents a reconciliation of net income and comprehensive income, the most comparable GAAP financial measure, to Adjusted EBITDA for each of the periods indicated:
|
| | | | | | | | | | | | | | | | |
|
| Three months ended October 31, | |
| Nine months ended October 31, | |
(in thousands) |
| 2014 |
|
| 2013 |
|
| 2014 |
|
| 2013 |
|
Net income and comprehensive income |
| $ | 3,049 |
|
| $ | 1,978 |
|
| $ | 8,795 |
|
| $ | 5,950 |
|
Income tax provision |
| 1,100 |
|
| 1,280 |
|
| 5,047 |
|
| 3,724 |
|
Depreciation and amortization |
| 1,134 |
|
| 742 |
|
| 2,960 |
|
| 1,913 |
|
Amortization of acquired intangible assets |
| 409 |
|
| 409 |
|
| 1,227 |
|
| 1,227 |
|
Loss on revaluation of redeemable convertible preferred stock derivative liability |
| — |
|
| 109 |
|
| 735 |
|
| 109 |
|
Other (1) |
| 373 |
|
| 43 |
|
| 972 |
|
| 113 |
|
Total adjustments |
| $ | 3,016 |
|
| $ | 2,583 |
|
| $ | 10,941 |
|
| $ | 7,086 |
|
Adjusted EBITDA |
| $ | 6,065 |
|
| $ | 4,561 |
|
| $ | 19,736 |
|
| $ | 13,036 |
|
| |
(1) | For the three and nine months ended October 31, 2014, Other consisted of interest income of $(9) and $(9), interest expense of $0 and $0, miscellaneous taxes of $55 and $188, and stock-based compensation expense of $327 and $793, respectively. For the three and nine months ended October 31, 2013, Other consisted of interest income of $(12) and $(36), interest expense of $11 and $30, miscellaneous taxes of $31 and $75, and stock-based compensation expense of $13 and $44, respectively. |
Key components of our results of operations
Revenue
The following table sets forth our revenue for the periods indicated:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended October 31, | |
|
|
|
|
| Nine months ended October 31, | |
|
|
|
|
(in thousands, except percentages) | 2014 |
|
| 2013 |
|
| $ Change |
|
| % Change |
|
| 2014 |
|
| 2013 |
|
| $ Change |
|
| % Change |
|
Account fee revenue | $ | 11,086 |
|
| $ | 7,496 |
|
| $ | 3,590 |
|
| 48 | % |
| $ | 32,022 |
|
| $ | 21,721 |
|
| $ | 10,301 |
|
| 47 | % |
Custodial fee revenue | 6,196 |
|
| 4,816 |
|
| 1,380 |
|
| 29 | % |
| 17,557 |
|
| 13,913 |
|
| 3,644 |
|
| 26 | % |
Card fee revenue | 4,317 |
|
| 2,853 |
|
| 1,464 |
|
| 51 | % |
| 12,848 |
|
| 8,929 |
|
| 3,919 |
|
| 44 | % |
Other revenue | 263 |
|
| 83 |
|
| 180 |
|
| 217 | % |
| 557 |
|
| 291 |
|
| 266 |
|
| 91 | % |
Total revenue | $ | 21,862 |
|
| $ | 15,248 |
|
| $ | 6,614 |
|
| 43 | % |
| $ | 62,984 |
|
| $ | 44,854 |
|
| $ | 18,130 |
|
| 40 | % |
We generate revenue from three primary sources: account fees, custodial fees and card fees. We also generate other revenue, primarily from marketing materials that we produce for our Network Partners.
Account fee revenue. We earn account fee revenue from the fees we charge our Network Partners, employer clients and individual members for the administration services we provide in connection with the Health Savings Accounts ("HSA") and Health Reimbursement Arrangements ("HRA") we offer. Our fees are generally fixed for the duration of our agreement with the relevant customer, which is typically three to five years, and are paid to us on a monthly basis. We recognize revenue on a monthly basis as services are rendered under our written service agreements.
Custodial fee revenue. We earn custodial revenue from our AUM held in trust with our FDIC-insured custodial depository bank partners and our custodial investment partners. As a non-bank custodian, we deposit our cash AUM with our various bank partners pursuant to contracts that (i) have terms up to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances deposited with the relevant bank partner, and (iii) have minimum and maximum required deposit balances. We earn custodial fees on our cash AUM that are based on the interest rates offered to us by these bank partners. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA assets in mutual funds through our custodial investment partner. We receive a recordkeeping fee related to such investment AUM.
Card fee revenue. We earn card fee revenue each time one of our members uses one of our payment cards to make a qualified purchase. These card fees are collected each time a member “swipes” our payment card to pay a healthcare-related expense. We recognize card fee revenue monthly based on reports received from third parties, namely, the card-issuing bank and the card processor.
Cost of services
Cost of services includes costs related to servicing member accounts, managing customer and partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations, and other operating costs related to servicing our members. Other components of cost of services include interest paid to members on cash AUM and card costs incurred in connection with processing card transactions for our members.
Account costs. Account costs include the account servicing costs described above. Additionally, for new accounts, we incur on-boarding costs associated with the new accounts, such as new member welcome kits and the cost associated with issuance of new payment cards.
Custodial costs. Custodial costs are comprised of interest we pay to our HSA Members and fees we pay to banking consultants whom we use to help secure agreements with our FDIC-insured custodial depository banking partners. We pay interest to HSA Members on a tiered basis. The interest rates we pay to HSA Members can be changed at any time upon required notice, which is typically 30 days.
Card costs. Card costs are comprised of costs we incur in connection with processing payment card transactions initiated by our members. Due to the substantiation requirement on RA-linked payment card transactions, which is the requirement that we confirm each purchase involves a qualified medical expense as defined under applicable law, payment card costs are higher for RA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the card transaction.
Other costs. Other costs are comprised of costs of marketing materials that we produce for our Network Partners.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of services, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including the fees we charge per account, interest rates, how many services we deliver per account, and card processing costs per account. We expect our annual gross margin to remain relatively steady over the near term, although our gross margin could fluctuate from period to period depending on the interplay of these factors.
Operating expenses
Sales and marketing. Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense (such as office rent, supplies, and other overhead expenses) allocations.
We expect our sales and marketing expenses to increase for the foreseeable future as we continue to increase the size of our sales and marketing organization and expand into new markets. However, on an annual basis, we expect our sales and marketing expenses to decrease slightly as a percentage of our total revenue over the near term. Our sales and marketing expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our sales and marketing expenses.
Technology and development. Technology and development expenses include personnel and related expenses for software engineering, information technology, security and compliance, and product development. Technology and development expenses also include outsourced software engineering services, the costs of operating our on-demand technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development of our proprietary system. On an annual basis, we expect our technology and development expenses to increase as a percentage of our total revenue over the near term as a result of higher amortization costs related to our planned capital expenditures to improve the architecture of our proprietary system. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses.
General and administrative. General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, and people departments. They also include depreciation, amortization, stock-based compensation and common expense allocations.
We expect our general and administrative expenses to increase for the foreseeable future due to the additional legal, accounting, insurance, investor relations and other public company costs that we will incur as a new public company, as well as other costs associated with continuing to grow our business. Looking forward, we expect our general and administrative expenses to remain steady as a percentage of our total revenue over the near term. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.
Amortization of acquired intangible assets. Amortization of acquired intangible assets results from our acquisition of intangible member assets. We acquired these intangible member assets from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We evaluate these assets for impairment at least each year, or at a triggering event.
Other expense
Other expense primarily consists of interest expense, loss on revaluation of warrants and loss on revaluation of our derivative liability associated with our series D-3 redeemable convertible preferred stock. We continued to record adjustments to the fair value of the derivative liability associated with our series D-3 redeemable convertible preferred stock until March 31, 2014, at which time the remeasurements ceased. As a result, during the nine months ended October 31, 2014, we recorded a loss on revaluation of this derivative liability. However, as a result of our modifications of our series D-3 redeemable convertible preferred stock on March 31, 2014, we reclassified the aggregate fair value of the derivative liability associated with our series D-3 redeemable convertible preferred stock to additional paid-in capital and we ceased to record any related fair value adjustments.
Income tax provision
We are subject to federal and state income taxes in the United States based on a calendar tax year that differs from our fiscal year-end for financial reporting purposes. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. As of October 31, 2014, we remain in a net deferred tax liability position. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Due to the positive evidence of taxable income coupled with forecasted profitability, no valuation allowance was required as of October 31, 2014.
Results of operations
The following table sets forth our results of operations for the specified periods. The period-to-period comparisons of results are not necessarily indicative of results for future periods.
|
| | | | | | | | | | | | | | | | |
|
| Three months ended October 31, | |
| Nine months ended October 31, | |
(in thousands) |
| 2014 |
|
| 2013 |
|
| 2014 |
|
| 2013 |
|
Revenue |
|
|
|
|
|
|
|
|
Account fee revenue |
| $ | 11,086 |
|
| $ | 7,496 |
|
| $ | 32,022 |
|
| $ | 21,721 |
|
Custodial fee revenue |
| 6,196 |
|
| 4,816 |
|
| 17,557 |
|
| 13,913 |
|
Card fee revenue |
| 4,317 |
|
| 2,853 |
|
| 12,848 |
|
| 8,929 |
|
Other revenue |
| 263 |
|
| 83 |
|
| 557 |
|
| 291 |
|
Total revenue |
| 21,862 |
|
| 15,248 |
|
| 62,984 |
|
| 44,854 |
|
Cost of services |
|
|
|
|
|
|
|
|
Account costs |
| 7,057 |
|
| 4,977 |
|
| 20,188 |
|
| 14,677 |
|
Custodial costs |
| 1,050 |
|
| 858 |
|
| 2,994 |
|
| 2,737 |
|
Card costs |
| 1,467 |
|
| 1,006 |
|
| 4,284 |
|
| 2,989 |
|
Other costs |
| 56 |
|
| 29 |
|
| 58 |
|
| 71 |
|
Total cost of services |
| 9,630 |
|
| 6,870 |
|
| 27,524 |
|
| 20,474 |
|
Gross profit |
| 12,232 |
|
| 8,378 |
|
| 35,460 |
|
| 24,380 |
|
Operating expenses |
|
|
|
|
|
|
|
|
Sales and marketing |
| 2,275 |
|
| 1,876 |
|
| 6,829 |
|
| 5,458 |
|
Technology and development |
| 2,811 |
|
| 1,803 |
|
| 7,299 |
|
| 5,131 |
|
General and administrative |
| 2,443 |
|
| 894 |
|
| 5,252 |
|
| 2,629 |
|
Amortization of acquired intangible assets |
| 409 |
|
| 409 |
|
| 1,227 |
|
| 1,227 |
|
Total operating expenses |
| 7,938 |
|
| 4,982 |
|
| 20,607 |
|
| 14,445 |
|
Income from operations |
| 4,294 |
|
| 3,396 |
|
| 14,853 |
|
| 9,935 |
|
Other expense |
|
|
|
|
|
|
|
|
Loss on revaluation of redeemable convertible preferred stock derivative
|
| — |
|
| (109 | ) |
| (735 | ) |
| (109 | ) |
Other expense, net |
| (145 | ) |
| (29 | ) |
| (276 | ) |
| (152 | ) |
Total other expense |
| (145 | ) |
| (138 | ) |
| (1,011 | ) |
| (261 | ) |
Income before income taxes |
| 4,149 |
|
| 3,258 |
|
| 13,842 |
|
| 9,674 |
|
Income tax provision |
| 1,100 |
|
| 1,280 |
|
| 5,047 |
|
| 3,724 |
|
Net income and comprehensive income |
| $ | 3,049 |
|
| $ | 1,978 |
|
| $ | 8,795 |
|
| $ | 5,950 |
|
The following table presents the components of our results of operations for the periods indicated as a percent of our total revenue:
|
| | | | | | | | | | | | |
|
| Three months ended October 31, | |
| Nine months ended October 31, | |
|
| 2014 |
|
| 2013 |
|
| 2014 |
|
| 2013 |
|
Revenue |
|
|
|
|
|
|
|
|
Account fee revenue |
| 51 | % |
| 49 | % |
| 51 | % |
| 48 | % |
Custodial fee revenue |
| 28 | % |
| 31 | % |
| 28 | % |
| 31 | % |
Card fee revenue |
| 20 | % |
| 19 | % |
| 20 | % |
| 20 | % |
Other revenue |
| 1 | % |
| 1 | % |
| 1 | % |
| 1 | % |
Total revenue |
| 100 | % |
| 100 | % |
| 100 | % |
| 100 | % |
Cost of services |
|
|
|
|
|
|
|
|
Account costs |
| 32 | % |
| 33 | % |
| 32 | % |
| 33 | % |
Custodial costs |
| 5 | % |
| 6 | % |
| 5 | % |
| 6 | % |
Card costs |
| 7 | % |
| 6 | % |
| 7 | % |
| 7 | % |
Other costs |
| — | % |
| — | % |
| — | % |
| — | % |
Total cost of services |
| 44 | % |
| 45 | % |
| 44 | % |
| 46 | % |
Gross profit |
| 56 | % |
| 55 | % |
| 56 | % |
| 54 | % |
Operating expenses |
|
|
|
|
|
|
|
|
Sales and marketing |
| 10 | % |
| 12 | % |
| 11 | % |
| 12 | % |
Technology and development |
| 13 | % |
| 12 | % |
| 12 | % |
| 11 | % |
General and administrative |
| 11 | % |
| 6 | % |
| 8 | % |
| 6 | % |
Amortization of acquired intangible assets |
| 2 | % |
| 3 | % |
| 2 | % |
| 3 | % |
Total operating expenses |
| 36 | % |
| 33 | % |
| 33 | % |
| 32 | % |
Income from operations |
| 20 | % |
| 22 | % |
| 23 | % |
| 22 | % |
Other expense |
|
|
|
|
|
|
|
|
Loss on revaluation of redeemable convertible preferred stock derivative
|
| — | % |
| (1 | )% |
| (1 | )% |
| — | % |
Other expense, net |
| (1 | )% |
| — | % |
| — | % |
| — | % |
Total other expense |
| (1 | )% |
| (1 | )% |
| (1 | )% |
| — | % |
Income before income taxes |
| 19 | % |
| 21 | % |
| 22 | % |
| 22 | % |
Income tax provision |
| 5 | % |
| 8 | % |
| 8 | % |
| 9 | % |
Net income and comprehensive income |
| 14 |